Long Intergenic Non-Coding RNAs have an Independent Impact on Survival in Multiple Myeloma

[1]  Hui-Ping Li,et al.  LncRNA MALAT‐1 Elevates HMGB1 to Promote Autophagy Resulting in Inhibition of Tumor Cell Apoptosis in Multiple Myeloma , 2017, Journal of cellular biochemistry.

[2]  D. Hao,et al.  Long Noncoding RNA CRNDE Promotes Multiple Myeloma Cell Growth by Suppressing miR-451. , 2017, Oncology research.

[3]  Huan Yao,et al.  LncRNA OIP5-AS1 loss-induced microRNA-410 accumulation regulates cell proliferation and apoptosis by targeting KLF10 via activating PTEN/PI3K/AKT pathway in multiple myeloma , 2017, Cell Death & Disease.

[4]  N. Munshi,et al.  Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma , 2017, The New England journal of medicine.

[5]  Rob Patro,et al.  Salmon provides fast and bias-aware quantification of transcript expression , 2017, Nature Methods.

[6]  A. Neri,et al.  In Silico Characterization of miRNA and Long Non-Coding RNA Interplay in Multiple Myeloma , 2016, Genes.

[7]  J. Mendell.  Targeting a Long Noncoding RNA in Breast Cancer. , 2016, The New England journal of medicine.

[8]  J. Rinn,et al.  Integrative analyses reveal a long noncoding RNA-mediated sponge regulatory network in prostate cancer , 2016, Nature Communications.

[9]  M. Robinson,et al.  Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences , 2015, F1000Research.

[10]  F. Strozzi,et al.  Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma , 2016, Oncotarget.

[11]  N. Munshi,et al.  miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth , 2016, Blood Cancer Journal.

[12]  Maite Huarte.  The emerging role of lncRNAs in cancer , 2015, Nature Medicine.

[13]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[14]  Jan-Gowth Chang,et al.  MALAT1 long non-coding RNA is overexpressed in multiple myeloma and may serve as a marker to predict disease progression , 2014, BMC Cancer.

[15]  Wenzhuo Zhuang,et al.  Activation of LTBP3 Gene by a Long Noncoding RNA (lncRNA) MALAT1 Transcript in Mesenchymal Stem Cells from Multiple Myeloma* , 2014, The Journal of Biological Chemistry.

[16]  Howard Y. Chang,et al.  Dicer-microRNA-Myc circuit promotes transcription of hundreds of long noncoding RNAs , 2014, Nature Structural &Molecular Biology.

[17]  K. Morris,et al.  The rise of regulatory RNA , 2014, Nature Reviews Genetics.

[18]  Charity W. Law,et al.  voom: precision weights unlock linear model analysis tools for RNA-seq read counts , 2014, Genome Biology.

[19]  Parantu K. Shah,et al.  The shaping and functional consequences of the dosage effect landscape in multiple myeloma , 2013, BMC Genomics.

[20]  Gareth J. Morgan,et al.  A gene expression signature for high-risk multiple myeloma , 2012, Leukemia.

[21]  David G. Knowles,et al.  The GENCODE v7 catalog of human long noncoding RNAs: Analysis of their gene structure, evolution, and expression , 2012, Genome research.

[22]  Bronwen L. Aken,et al.  GENCODE: The reference human genome annotation for The ENCODE Project , 2012, Genome research.

[23]  E. Bandrés,et al.  MiRNAs and LincRNAs: Could They Be Considered as Biomarkers in Colorectal Cancer? , 2012, International journal of molecular sciences.

[24]  D. Louis,et al.  Maternally expressed gene 3, an imprinted noncoding RNA gene, is associated with meningioma pathogenesis and progression. , 2010, Cancer research.

[25]  M. Robinson,et al.  A scaling normalization method for differential expression analysis of RNA-seq data , 2010, Genome Biology.

[26]  Laurence Lodé,et al.  Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Anthony Boral,et al.  Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. , 2006, Blood.

[28]  Yongsheng Huang,et al.  A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. , 2006, Blood.

[29]  W. Hiddemann,et al.  A four-gene LincRNA expression signature predicts risk in multiple cohorts of acute myeloid leukemia patients , 2018, Leukemia.

[30]  N. Munshi,et al.  Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis , 2017, JAMA oncology.